These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37227250)

  • 1. Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer Phenotype.
    Chen X; Adhikary G; Newland JJ; Xu W; Keillor JW; Weber DJ; Eckert RL
    Mol Cancer Res; 2023 Sep; 21(9):922-932. PubMed ID: 37227250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype.
    Chen X; Adhikary G; Shrestha S; Xu W; Keillor JW; Naselsky W; Eckert RL
    Mol Cancer Res; 2021 Dec; 19(12):2026-2035. PubMed ID: 34593609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.
    Chen X; Adhikary G; Newland JJ; Xu W; Ma E; Naselsky W; Eckert RL
    Mol Carcinog; 2023 Jan; 62(1):90-100. PubMed ID: 35848131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype.
    Naselsky W; Adhikary G; Shrestha S; Chen X; Ezeka G; Xu W; Friedberg JS; Eckert RL
    Mol Carcinog; 2022 Jun; 61(6):537-548. PubMed ID: 35319795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.
    Rorke EA; Adhikary G; Szmacinski H; Lakowicz JR; Weber DJ; Godoy-Ruiz R; Puranik P; Keillor JW; Gates EWJ; Eckert RL
    Mol Carcinog; 2022 Jan; 61(1):19-32. PubMed ID: 34610184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulforaphane inhibits CD44v6/YAP1/TEAD signaling to suppress the cancer phenotype.
    Chen X; Adhikary G; Ma E; Newland JJ; Naselsky W; Xu W; Eckert RL
    Mol Carcinog; 2023 Feb; 62(2):236-248. PubMed ID: 36285644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
    Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
    Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
    Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
    Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Outside-In Journey of Tissue Transglutaminase in Cancer.
    Sima LE; Matei D; Condello S
    Cells; 2022 May; 11(11):. PubMed ID: 35681474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death.
    Aplin C; Zielinski KA; Pabit S; Ogunribido D; Katt WP; Pollack L; Cerione RA; Milano SK
    Commun Biol; 2024 Aug; 7(1):982. PubMed ID: 39134806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
    Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
    Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.
    Lin CY; Tsai PH; Kandaswami CC; Chang GD; Cheng CH; Huang CJ; Lee PP; Hwang JJ; Lee MT
    Mol Cancer; 2011 Jul; 10():87. PubMed ID: 21777419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
    Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
    Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.
    Fisher ML; Kerr C; Adhikary G; Grun D; Xu W; Keillor JW; Eckert RL
    Cancer Res; 2016 Dec; 76(24):7265-7276. PubMed ID: 27780825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transglutaminase is a tumor cell and cancer stem cell survival factor.
    Eckert RL; Fisher ML; Grun D; Adhikary G; Xu W; Kerr C
    Mol Carcinog; 2015 Oct; 54(10):947-58. PubMed ID: 26258961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2.
    Bianchi N; Brugnoli F; Grassilli S; Bourgeois K; Keillor JW; Bergamini CM; Aguiari G; Volinia S; Bertagnolo V
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
    Lee J; Yakubov B; Ivan C; Jones DR; Caperell-Grant A; Fishel M; Cardenas H; Matei D
    Neoplasia; 2016 Nov; 18(11):689-698. PubMed ID: 27792935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-associated Fibroblasts induce epithelial-mesenchymal transition
    Jia C; Wang G; Wang T; Fu B; Zhang Y; Huang L; Deng Y; Chen G; Wu X; Chen J; Pan Y; Tai Y; Liang J; Li X; Hu K; Xie B; Li S; Yang Y; Chen G; Zhang Q; Liu W
    Int J Biol Sci; 2020; 16(14):2542-2558. PubMed ID: 32792856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomics Studies Reveal Functions of Transglutaminase 2 in Breast Cancer Cells Using Membrane Permeable and Impermeable Inhibitors.
    Ancona P; Trentini A; Terrazzan A; Grassilli S; Navals P; Gates EWJ; Rosta V; Cervellati C; Bergamini CM; Pignatelli A; Keillor JW; Taccioli C; Bianchi N
    J Mol Biol; 2024 May; 436(10):168569. PubMed ID: 38604527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
    Ayinde O; Wang Z; Griffin M
    Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.